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ABSTRACT
Introduction: An Excel (Microsoft
Corporation) model was adapted to estimate
the short-term (1-year) cost effectiveness of
insulin detemir (IDet) versus neutral
protamine Hagedorn (NPH) insulin in patients
initiating insulin treatment with type 1 diabetes
mellitus (T1DM) and type 2 diabetes mellitus
(T2DM) in Spain.
Methods: Clinical benefits included the
non-severe hypoglycemia rate for T1DM and
T2DM, and weight change for T2DM. Three
scenarios were included with different
hypoglycemia rates estimated on the basis of
clinical trials and observational studies. Costs,
estimated from perspective of the Spanish
Public Healthcare System (Euros 2014),
included insulin treatment and non-severe
hypoglycemia management costs. Non-severe
hypoglycemia, defined as a self-managed event,
implied the use of extra glucose testing strips
and a general practitioner visit during the week
following the event for 25% of patients. An
average disutility value was associated to
non-severe hypoglycemia events and, for
T2DM, to one body mass index unit gain to
calculate quality-adjusted life years (QALYs).
Results: For the three scenarios a range of
0.025–0.076 QALYs for T1DM and
0.014–0.051 QALYs for T2DM were gained for
IDet versus NPH due to non-severe
hypoglycemia and weight gain avoidance, in
return of an incremental cost of €145–192 for
T1DM and €128–206 for T2DM. This resulted in
the IDet versus NPH incremental
cost-effectiveness ratio (ICER) ranging between
€1910/QALY and €7682/QALY for T1DM and
€2522/QALY and €15,009/QALY for T2DM.
Conclusion: IDet was a cost-effective
alternative to NPH insulin in the first year of
treatment of patients with T1DM and patients
with T2DM in Spain, with ICERs under the
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INTRODUCTION
Diabetes mellitus is a group of heterogeneous
metabolic disorders with the common features
of hyperglycemia and glucose intolerance,
which affects about 10.8% of the Spanish
population [1]. In patients with type 1
diabetes mellitus (T1DM), insulin endogenous
secretion is impaired, while patients with type 2
diabetes mellitus (T2DM), which represent
about 90% of diabetes cases, do not respond to
endogenous insulin properly [2]. Therefore,
insulin therapy is indicated for all patients
with T1DM as they are completely dependent
on exogenous insulin; however, only patients
with T2DM who are unable to achieve adequate
glycemic control by other measures (exercise,
diet, and/or other antidiabetic agents) will
receive insulin treatment [3].
The main treatment goal in people with
diabetes is to achieve a normal blood glucose
level to reduce the risk of microvascular and
macrovascular long-term complications [2];
however, acute hypoglycemia represents the
most common adverse event associated with
insulin treatment [4] and have a substantial
economic and social impact [5]. Therefore, the
principle of ‘basal’ insulin use is the
optimization of glycemic control, minimizing
the risk of hypoglycemia to improve
health-related quality-of-life (HRQoL) and
adherence to treatment [6].
Either intermediate-acting (neutral
protamine Hagedorn [NPH]) or long-acting
(insulin glargine or insulin detemir [IDet])
formulations may be used as initial basal
therapy aimed to control blood glucose
between meals and overnight [6]. Long-acting
insulin analogs more accurately mimic the
physiological human insulin profile and
provide an alternative to human insulins such
as NPH insulin [6]. In addition, long-acting
insulins are associated with fewer hypoglycemia
events and less weight gain than NPH [7, 8].
These improvements lead to better
quality-adjusted life years (QALYs) compared
with NPH insulin [9, 10].
Hypoglycemia can be classified on the basis
of the event management. While severe
hypoglycemia requires the assistance from
another person, sometimes from a medical
professional and even hospital care [11],
non-severe hypoglycemia is defined as an
episode that can be managed by the patients
themselves. Although non-severe hypoglycemic
events are easier to manage, they are more
common than severe events [12]. Recurrent
episodes of non-severe hypoglycemia may
cause behavioral changes and cognitive
impairment, leading patients to develop fear
of hypoglycemia [13], reducing HRQoL, and
affecting treatment adherence [13–15].
Furthermore, severe and non-severe
hypoglycemia is associated with direct
healthcare costs and indirect costs due to
productivity loss [11, 16, 17]. Weight gain is
also commonly associated with insulin therapy,
especially among patients with T2DM [18], and
is linked to an increased risk of cardiovascular
morbidity and mortality [19].
For these reasons, the importance of
controlling hypoglycemia events in the
management of both T1DM and T2DM has
been recognized in the reimbursement process
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in several countries. Insulin analogs with a
reduced rate of hypoglycemia and weight gain,
like IDet, may provide long- and short-term
health benefits with respect to traditional
human insulins [20, 21]; however, this clinical
benefit and improved quality of life comes with
the additional pharmacy costs associated with
IDet.
Thus, we aimed to estimate the cost
effectiveness of IDet compared with NPH
insulin when initiating insulin treatment in
patients with T1DM and patients with T2DM
using a conservative short-term modeling
approach from the perspective of the Spanish
National Health System (NHS).
The present study is based on the treatment
benefits associated with a reduction in
hypoglycemic events and less weight gain as
observed in clinical trials and observational
studies. Given the short-term design of these
studies, a short-term modeling approach is the
most conservative option to include clinical
data from independent sources and to avoid
unrealistic extrapolation derived from
long-term horizons. As this kind of
cost-effectiveness analysis (CEA) for IDet
versus NPH is only available for Scandinavian
countries [10, 22], this is the first study, to our
knowledge, from the perspective of the Spanish
NHS.
METHODS
Cost-Effectiveness Model
A 1-year CEA model was developed in Excel
2007 (Microsoft Corporation) to compare basal
insulin treatment with IDet against NPH insulin
for the management of T1DM and T2DM. For
the current analysis, input parameters of the
model were adapted to the Spanish NHS. The
clinical benefit was defined in terms of QALYs
and reflects the effects of hypoglycemic events
and weight gain. Only direct health care costs
are included (insulins and management of
minor hypoglycemic events).
Structure of the Model
The structure of the model is based on two
Scandinavian studies: Valentine et al. [10]
(T1DM) and Ridderstra˚le et al. [22] (T2DM). To
assess the comparison, two arms are considered,
one receiving IDet and one receiving NPH
insulin. Each arm is provided with input data
obtained from clinical trials [20, 21] and
observational studies [23, 24]. As the model
was designed to only take into account
statistically significant clinical benefits, only
the rate of non-severe hypoglycemia for both
T1DM and T2DM [10] and the weight change
from baseline for T2DM [22] are included in the
evaluation. Other clinical parameters, such as
severe hypoglycemic events and glycated
hemoglobin control were excluded as their
differences were found to be not significant.
Disutility associated to weight gain and
hypoglycemic events is used to estimate
QALYs and the incremental cost-effectiveness
ratio (ICER; €/QALY) is estimated as the relation
between QALYs and costs of one arm versus
another.
Study Population
The population consisted in two hypothetical
cohorts of patients with either T1DM or T2DM
taking up insulin treatment. The number of
individuals in the cohort is irrelevant to the
result as cost and clinical outcomes are
expressed as average yearly costs and rates of
event per patient.
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Treatments to Compare
One cohort of patients was treated with IDet
and the other with NPH. The daily dose was
assumed to be 40 IU/day [10], which is the
defined daily dose (DDD) indicated by the
World Health Organization (WHO) [25].
Time Horizon and Perspective
To estimate the cost-effectiveness of IDet
compared to NPH in patients with T1DM and
patients with T2DM in Spain, the time horizon
considered was one year. The perspective
adopted was that of the Spanish NHS.
Clinical Data Inputs
Due to the lack of a study which examines
hypoglycemia rates, hypoglycemia IDet/NPH
ratios, and weight changes associated to both
treatment arms (NPH and IDet for patients with
T1DM and patients with T2DM) we have
collected clinical data inputs from
independent robust sources which are
summarized below.
Hypoglycemia Rates
Three scenarios were estimated in which the
NPH arm was assigned three different
hypoglycemia rates (Table 1). Two scenarios
were defined based on data from an
observational prospective study conducted in
six secondary care diabetes centers in the UK
over 9–12 months [23]. The UK Hypoglycemia
Study [23] hypothesized that diabetes type and
the duration of insulin treatment influenced
the risk of hypoglycemia. To test this
hypothesis, they explored the epidemiology of
hypoglycemia in individuals with diabetes. A
total of 383 patients aged 17–75 years were
included in three treatment groups for T2DM:
(1) sulfonylurea, (2) insulin for\2 years, and (3)
insulin for [5 years, and into two treatment
groups for T1DM: (1) insulin for \5 years and
(2) insulin for[15 years and asked to self-report
all non-severe (self-treated) and severe
hypoglycemic episodes (requiring medical
assistance). Hypoglycemic episodes were
recorded using two complementary methods:
Self-reported, when a patient experiences
symptoms usually associated with
hypoglycemia, or biochemical, reporting all
episodes with glucose levels \3.0 mmol/L. The
hypoglycemia rates were extracted from
self-reported hypoglycemic episodes
corresponding to the cohort of patients that
recently began insulin treatment. The follow-up
period ranged from a mean of 8.8 [standard
deviation (SD) 2.6] months in
sulfonylurea-treated subjects to 10.3 (SD 3.0)
months in longstanding T1DM. As a result, for
patients with T1DM treated\5 years a mean of
35.5 [95% confidence interval (CI) 22.8–48.2]
events were self-reported, while a mean of 4.08
(95% CI 2.4–5.8) episodes were reported for
patients with T2DM treated \2 years. From a
cohort with more than 15 years of insulin
treatment, a mean of 29.0 (95% CI 16.4–41.8)
events for T1DM and 10.2 (95% CI 5.4–15.0)
episodes for T2DM were selected.
A more recent observational cross-sectional
study carried out in Spain [24] was chosen to
estimate the third scenario, describing the
frequency of self-reported non-severe and
severe hypoglycemic events in patients with
T1DM and patients with T2DM. A total of 630
individuals [n = 294 (47%) with T1DM and
n = 336 (53%) with T2DM] aged 15 years or
older and receiving insulin were enrolled to fill
out a questionnaire survey, and a total of
506 patients completed the four questionnaires
comprised in the study. The first questionnaire
collected the self-reported frequency of
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non-severe and severe hypoglycemia in the
previous year, while the other three
questionnaires were administered weekly, to
record the frequency of non-severe and severe
hypoglycemia in the preceding 7 days. From
this study, a mean yearly non-severe
hypoglycemia rate of 88.0 for T1DM and of
18.3 for T2DM receiving basal-only therapy
based on long-acting insulin were selected to
feed the model.
Hypoglycemia IDet/NPH Ratios
Lacking a robust source for the non-severe
hypoglycemia IDet/NPH ratio, the IDet/NPH
rate ratio (RR) for overall hypoglycemic events
in patients with T1DM was extracted from a
systematic review and meta-analysis study
carried out by the Canadian Agency for Drugs
and Technologies in Health (CADTH) [21]. The
study aimed to evaluate the clinical efficacy and
safety of the long-acting insulin analogs
compared with intermediate- and long-acting
unmodified human insulins and oral
antidiabetic drugs (OADs) for the treatment of
T1DM, T2DM, and gestational diabetes [21].
MedLine, Embase, and BIOSIS previews and the
Cochrane library were searched for the terms
‘‘diabetes,’’ ‘‘long-acting insulin,’’ and
‘‘short-acting insulin analogs,’’ and filtered by
randomized controlled trials (RCTs), over the
period of 1990–2007. Outcomes of interest
included glycemic control (glycosylated
hemoglobin or A1C, fasting plasma glucose),
hypoglycemia, body weight, quality of life,
patient satisfaction, healthcare utilization, and
long-term complications of diabetes. From a
meta-analysis of six RCTs (2109 patients), the
reduction of non-severe hypoglycemia was
Table 1 NSH rates assigned to NPH cohort and estimated NSH rates for IDet cohort in patients with T1DM and patients
with T2DM
Source Cohort NPH NSH rate
(NSH/patient year)
[95% CI]
Overall
hypoglycemia
[21] IDet/
NPH RR
Approximate
NSH IDet rate
(NSH/patient year)
T1DM
UK Hypoglycemia Study
Group (2007) [23]
Insulin\5 years 35.5 [22.8–48.2] 0.84 35.5 9 0.84 = 29.82
UK Hypoglycemia Study
Group (2007) [23]
Insulin[15 years 29.0 [16.4–41.8] 0.84 29.0 9 0.84 = 24.36
Orozco-Beltra´n et al. (2014) [24] T1DM 88.0 0.84 88.0 9 0.84 = 73.92
T2DM
UK Hypoglycemia Study
Group (2007) [23]
Insulin\2 years 4.08 [2.4–5.8] 0.52 4.08 9 0.52 = 2.12
UK Hypoglycemia Study
Group (2007) [23]
Insulin[5 years 10.2 [5.4–15.0] 0.52 10.2 9 0.52 = 5.30
Orozco-Beltra´n et al. (2014) [24] T2DM, T2BOT 18.3 0.52 18.3 9 0.52 = 9.52
IDet Insulin detemir, NPH Neutral protamine Hagedorn, NSH Non-severe hypoglycemia, RR Rate ratio, T1DM Type 1
diabetes mellitus, T2BOT Treated with basal insulin plus oral therapy, T2DM Type 2 diabetes mellitus
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statistically significant when IDet was compared
with NPH, with an IDet/NPH overall
hypoglycemia RR of 0.84 (95% CI 0.74–0.97).
On the other hand, IDet/NPH RR was
estimated at 0.52 (0.44–0.61) for patients with
T2DM [20, 22], on the basis of a multicenter,
randomized, open-label, 3-arm (morning or
evening IDet vs. evening NPH), parallel-group
clinical trial [20]. This trial was conducted in 91
centers across Europe and the United States over
20 weeks. It was aimed at comparing the
effectiveness and tolerability of IDet
administered once daily with those of NPH
insulin. Patients eligible for inclusion were
adults, with a body mass index (BMI) B40 kg/
m2, who had a diagnosis of T2DM of at least
12 months, and were receiving C1 OAD but
were insulin naı¨ve. A subanalysis comparing
IDet clinical outcomes by time of
administration was also conducted. A total of
504 patients were enrolled (285 male, 219
female); patients were randomly assigned in a
1:1:1 ratio to receive either IDet before breakfast
(n = 168); IDet in the evening (n = 170), or NPH
insulin in the evening (n = 166). When evening
administration of IDet was compared with NPH,
the hypoglycemic RR obtained was 0.52 for
patients with T2DM.
Considering the rate of non-severe
hypoglycemia in the NPH arm and the overall
hypoglycemia IDet/NPH RR in T1DM [21] and
T2DM [20], the rate of approximate non-severe
hypoglycemia episodes for patients with T1DM
and patients with T2DM who received IDet was
calculated by multiplying the respective
hypoglycemic rate for patients receiving NPH
insulin by the IDet/NPH RR, as reported in
Table 1 for both T1DM and T2DM.
Weight
The same IDet versus NPH RCT described above
[20] was the source of the IDet versus NPH mean
weight change difference for patients with
T2DM. The study reported an increase in body
weight following insulin initiation in both
evening IDet and NPH insulin groups (0.7 vs.
1.6 kg, respectively) with respect to the baseline,
with the mean difference being 0.91 kg
(P\0.005) [20].
Source of Costs Data
Only pharmacy and non-severe hypoglycemia
management costs were included in the model.
Costs were computed from the perspective of
the Spanish NHS and are expressed in Euros of
the year 2014 [26]. Pharmacy daily costs are
detailed in Table 2. Pharmacy costs were
reimbursed by the Spanish NHS. IDet cost is
discounted by 7.5% (discount in force at the
time of the estimation, i.e., September 2014).
Non-severe hypoglycemia management
costs were assumed to consist only of the cost
of an average of 5.6 extra glucose test strips per
event, as it was considered that this would be
the only measurable cost of self-managed
hypoglycemia [10, 17, 22]. Additionally, it was
assumed that 25% of the cohort visits a general
practitioner as a consequence of a non-severe
hypoglycemic event, as is reported by Brod et al.
[17]. The non-severe hypoglycemia
management costs are detailed in Table 3.
Utilities
The utility value for symptomatic non-severe
hypoglycemia for patients with T1DM and
patients with T2DM was -0.0054, which was
calculated by averaging the utility associated to
nocturnal (-0.0067) and diurnal (-0.0041)
episodes [29].
For patients with T2DM, the utility value
assigned for the BMI increment was estimated
in -0.0100 per BMI unit increase [30]. To
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estimate the utility value assigned for weight
increments, weight changes were transformed
in BMI changes multiplying the weight change
by 0.346 (DBMI = Dweight/[height2];
considering the mean height of the Spanish
population is 1.7 m [31],
DBMI = Dweight 9 0.346).
Sensitivity Analysis
A one-way sensitivity analysis (OWSA) was
performed to assess model uncertainty. The
variables were assigned consecutively an upper
and a higher value to estimate the resulting
ICER in each case. Intervals included in the
analysis are detailed in Table 4 for both T1DM
and T2DM. The values of ICER obtained with
each parameter variation were represented
using tornado-type diagrams. Due to the small
differences in weight gain between both
treatment arms, an additional scenario was
evaluated dismissing the utility loss due to
BMI increase.
A probabilistic sensitivity analysis (PSA) with
1000 simulations was also performed to assess
model outcome stability when varying all
parameters at once, according to
suitable probability distribution [22].
Distributions considered for each parameter
were: log-normal for hypoglycemia rates and
RRs, normal for the weight changes, beta for
disutilities, and gamma for hypoglycemia costs
and insulin doses. Results were represented
using cost-effectiveness acceptability curves
and scatterplots.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Table 2 Daily drug costs from the perspective of the Spanish NHS
Drug Unit cost
(€/IU)
Source DDD Source Treatment cost/day
IDet (Levemir) 0.0310 [26] 40 IU/day [25] €0.0310/IU 9 40 IU/day = €1.2408
NPH insulin (Insulatard Flexpen) 0.0162 [26] 40 IU/day [25] €0.0162/IU 9 40 IU/day = €0.6496
DDD Daily deﬁned dose, IDet Insulin detemir, NHS National Health System, NPH Neutral protamine Hagedorn
Table 3 Resource use and cost per NSH event in Spain
Item Unit
cost
Source Resource use Treatment
cost/NSH
Cost of NSH Glycometer strip €0.4524/strip [27] 5.600 strips/NSH €0.4524/
strip 9 5.600 strips/
NSH ? €9.9600/
visit 9  visit/
NSH = €5.0234
GP visit €9.9600/visit [28] 1 GP visit for  of patients
following the NSH
GP General practitioner, NSH Non-severe hypoglycemia
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RESULTS
Base Case
Due to lower non-severe hypoglycemia rates in
patients with T1DM, IDet treatment yields an
improvement with respect to NPH insulin
ranging between 0.025 and 0.076 QALYs, at an
incremental cost between €145 and €192 per
patient per year for the three scenarios
considered in the base case. Therefore, the
ICER for IDet versus NPH insulin was
estimated at €1910/QALY to €7682/QALY,
depending on the three different
hypoglycemia rates considered (Table 5).
For patients with T2DM, IDet was associated
with significantly fewer non-severe
hypoglycemic episodes and less weight gain
compared to NPH insulin, resulting in a
0.014–0.051 QALY gain for the three base-case
scenarios, in return of an incremental cost of
€128–€206 for the Spanish NHS. Therefore, the
IDet versus NPH insulin ICER was estimated at
€2522/QALY to €15,009/QALY in Spain, in
relation to the three different hypoglycemia
rates considered (Table 5).
One-Way Sensitivity Analysis
OWSA was conducted for key input parameters.
Overall, results are detailed in Figs. 1 and 2 for
T1DM and T2DM, respectively. The variable
that has the highest impact on the ICER for
T1DM is IDet/NPH hypoglycemia RR, with ICER
values varying from €1965/QALY to €36,592/
QALY, when varying the IDet/NPH
hypoglycemia RR between 0.74 and 0.97. The
second variable with the highest impact on
ICER is the daily cost of IDet treatment, which
makes ICER decrease to €3152/QALY when
decreased by 20%, and increase to €9058/
QALY when increased by 20%. All otherT
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variables have reduced impacts on ICER (Fig. 1).
In T2DM, the variable with the highest impact
on ICER is IDet cost. When increasing or
decreasing it by 20%, the ICER varies between
€8408/QALY and €21,610/QALY. Disutility due
to weight gain is the second most sensitive
variable, making the ICER increase to €19,478/
QALY when it is not considered. NPH cost
Fig. 1 One-way sensitivity analyses for IDet versus NPH
for T1DM in Spain (for NPH non-severe hypoglycemia
rate = 35.5). UKHSG UK Hypoglycemic Study Group,
RR CI Rate ratio conﬁdence interval, ICER Incremental
cost-effectiveness ratio, IDet Insulin detemir, NPH Neutral
protamine Hagedorn, QALY Quality-adjusted life year, RR
Rate ratio, T2DM Type 2 diabetes mellitus
Fig. 2 One-way sensitivity analyses for IDet versus NPH
for T2DM in Spain (for NPH non-severe hypoglycemia
rate = 4.08). UKHSG UK Hypoglycemia Study Group,
RR CI Rate ratio conﬁdence interval, ICER Incremental
cost-effectiveness ratio, IDet Insulin detemir, NPH Neutral
protamine Hagedorn, QALY Quality-adjusted life year, RR
Rate ratio, T2DM Type 2 diabetes mellitus
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variation (±20%) induces a variation of ICER
slightly higher than €5000/QALY. All other
variables have a smaller impact on ICER (Fig. 2).
Probabilistic Sensitivity Analysis
Cost-effectiveness acceptability curves allow
estimation of the NHS willingness-to-pay for
an additional QALY at different ICER
thresholds. For the threshold value currently
accepted in Spain of €30,000/QALY, IDet has
89.5% and 78.7% probabilities of being cost
effective versus NPH for T1DM and T2DM,
respectively (Figs. 3, 4).
According to the cost-effectiveness
scatterplots, IDet has a 32.9% probability of
being more effective and less costly than NPH
(dominant) for T1DM (Fig. 5) and 20.7%
probability for T2DM (Fig. 6).
DISCUSSION
This direct and transparent short-term CEA was
planned to rely on statistically significant
efficacy differences between IDet and NPH;
therefore, only non-severe hypoglycemia rates
for T1DM and T2DM, and weight gain
differences for T2DM were included. The
model is based on previously published
short-term economical evaluations for
Scandinavian countries (Denmark, Finland,
the Netherlands, Norway, and Sweden), and,
to our knowledge, is the first of its kind in Spain.
This evaluation showed that due to lower
hypoglycemic rate and less weight gain, IDet
versus NPH insulin is associated with an ICER
that stays below the threshold commonly
accepted for Spain (€30,000/QALY) [32] both
in patients with T1DM and patients with T2DM,
and can, therefore, be considered as
cost-effective in this country.
In general, the model results are quite robust;
in fact, all estimated ICERs in the OWSA remain
below the cost-effectiveness acceptability
threshold implicitly mentioned above. The
only exception is attributing an IDet/NPH
hypoglycemia RR close to 1 (RR = 0.97; upper
extreme of the 95% CI from the CADTH
Fig. 3 Cost-effectiveness acceptability curves for IDet versus NPH for T1DM in Spain (for NPH non-severe hypoglycemia
rate = 35.5). IDet Insulin detemir, NPH Neutral protamine Hagedorn, T1DM Type 1 diabetes mellitus
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meta-analysis average [21]), for which IDet
would not be considered cost-effective with
respect to NPH in patients with T1DM. This is
because an RR close to 1 would imply that IDet
does not provide any relevant incremental
health benefit on hypoglycemia rate versus
Fig. 4 Cost-effectiveness acceptability curves for IDet versus NPH for T2DM in Spain (for NPH non-severe hypoglycemia
rate = 4.08). IDet Insulin detemir, NPH Neutral protamine Hagedorn, T2DM Type 2 diabetes mellitus
Fig. 5 Cost-effectiveness scatterplot for IDet versus NPH
for T1DM in Spain (for NPH non-severe hypoglycemia
rate = 35.5). IDet Insulin detemir, NPH Neutral
protamine Hagedorn, QALY Quality-adjusted life year,
T1DM Type 1 diabetes mellitus
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NPH; thus, its higher daily price would not be
justified. Another sensitive variable, in both
types of diabetes, is the treatment cost.
Increasing or decreasing the cost of IDet,
makes the ICER vary in an interval up to
€6000/QALY wide (T1DM). These estimations
are consistent with the structure of the model.
Moreover, PSA simulations reveal a probability
of cost-effectiveness at a €30,000/QALY
threshold of about 90% and 80% in T1DM
and T2DM, respectively.
The results of this evaluation must be read in
the context of its limitations. First, only the
short term is considered. This might
underestimate the real clinical benefits of IDet
with respect to NPH; in fact, the hypoglycemia
rate is expected to increase with treatment
duration [33].
With reference to the absolute rate of
non-severe hypoglycemia in the NPH
treatment arm, this is a crucial datum that
affects the cost-effectiveness of IDet versus NPH
for which the three scenarios were estimated in
the base-case analysis. The first two scenarios
use non-severe hypoglycemia rates coming
from the UK Hypoglycemia Study [23] which
is a reference observational study for
hypoglycemia in diabetic patients. From this
study, two non-severe hypoglycemia rates have
been selected: one corresponding to patients
with recent insulinization (\5 and\2 years for
T1DM and T2DM, respectively), and one
corresponding to patients with long-run
insulinization ([15 and [5 years for T1DM
and T2DM, respectively) [23]. The third
scenario is based on non-severe hypoglycemia
rates from a recently published observational
study performed in Spain [24], which should be
considered the closest to the ‘‘real-world’’
situation of the Spanish NHS, showing the
Fig. 6 Cost-effectiveness scatterplot for IDet versus NPH
for T2DM in Spain (for NPH non-severe hypoglycemia
rate = 4.08). IDet Insulin detemir, NPH Neutral
protamine Hagedorn, QALY Quality-adjusted life year,
T2DM Type 2 diabetes mellitus
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highest non-severe hypoglycemia rates. The
three scenarios all give cost-effective results
and contemplate hypoglycemia rates. It must
be considered that the non-severe
hypoglycemia rate of these studies was
assumed to correspond to treatment with
NPH, although insulin type information was
not available and most probably included
different insulin types. However, this is a
conservative assumption in that NPH is known
to be associated to higher hypoglycemia rates
than more modern insulin analogs [34]. In
addition, the use of an overall hypoglycemia
RR for IDet versus NPH, instead of a specific RR
for non-severe hypoglycemia episodes, due to
the lack of a robust source for this datum in the
literature, may be considered a limitation of the
model. Anyway, the approximated values that
are maintained from the original models by
Valentine et al. [10] and Ridderstra˚le et al. [22]
give conservative estimations of the non-severe
hypoglycemia RR, as already discussed by
Valentine et al. [10], and offer the advantage
of integrating data from a very controlled
setting (RCTs [20, 21]), with a setting that is
closer to the ‘‘real-world’’ data (observational
study [23]), as explained by Ridderstra˚le et al.
[22].
As the hypoglycemia rate was an overall
value (no distinction between nocturnal and
diurnal non-severe hypoglycemia events), the
utility values associated to diurnal and
nocturnal events [17] were averaged to obtain
a unique value. However, this simplification
was tested in the OWSA by assuming 100%
nocturnal or 100% diurnal events and
attributing the corresponding utility values. In
both ICER estimations, IDet was considered as
cost-effective with respect to NPH.
Another limitation may be the use of the
WHO DDD of insulin [25]. Even though
40 IU/day is not a ‘‘real-world’’ dose for
patients with diabetes, robust data in this
sense are not available due to the dosing
variability in clinical practice. Considering all
exposed assumptions, this may be considered a
conservative estimation.
Long-term cost effectiveness of IDet versus
NPH insulin in Spain was previously assessed for
basal-bolus therapy, together with four other
European countries (Belgium, France, Germany,
and Italy) [35]. This evaluation showed that, in
the long term, IDet is dominant (in Spain,
Belgium, and Germany) or very cost effective
(France and Italy) with respect to NPH, due to
the reduced cumulative incidence of most
diabetes-related complications over the patient
lifetime. Other long-term evaluations carried
out for Germany, Sweden, and the UK [9,
36–38] have also shown IDet long-term cost
effectiveness compared to NPH insulin in both
patients with T1DM and patients with T2DM.
However, short-term cost-effectiveness
analyses for IDet versus NPH are only available
for Scandinavian countries, estimating ICERs in
the range of €12,216/QALY to €16,568/QALY
(year 2010) for T1DM [10] and €21,768/QALY to
€28,349/QALY (year 2012) for T2DM [20] over a
1-year period.
Therefore, a short-term cost-effectiveness
estimation was needed in Spain to address the
requirements of healthcare decision makers for
whom short-term cost effectiveness may be
more relevant to immediate budget
considerations.
CONCLUSIONS
In conclusion, this analysis shows in a direct
manner that IDet can be considered
cost-effective with respect to NPH insulin in a
Spanish setting for the treatment of both
patients with T1DM and patients with T2DM,
with ICERs that are in line with or even smaller
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than those calculated for other European
countries, and in the range commonly
accepted for Spain.
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